M
Montserrat Camps
Researcher at Merck Serono
Publications - 73
Citations - 8670
Montserrat Camps is an academic researcher from Merck Serono. The author has contributed to research in topics: Mitogen-activated protein kinase & MAP2K7. The author has an hindex of 37, co-authored 73 publications receiving 8263 citations. Previous affiliations of Montserrat Camps include University of Barcelona & Merck KGaA.
Papers
More filters
Journal ArticleDOI
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
TL;DR: A compensatory mechanism of the surviving dopaminergic neurones as well as the participation of spare receptors is suggested to explain the lack of receptor modification after the lesion obtained as seen by the striatal reduction of dopamine and metabolites content, after MPTP administration.
Patent
Novel scintillation proximity assays for aminoglycoside binding molecules (abms)
Montserrat Camps,Chabert Christian,Dominique Perrin,Thierry Martin,Matthias P. Wymann,Christian Rommel +5 more
TL;DR: In this article, the scintillation proximity effect is exploited to identify and quantify Aminoglycoside Binding Molecules (ABMs), enzymes modifying such molecules, and compounds modulating the interaction between ABMs and either enzymes or aminoglycosides.
Journal ArticleDOI
Effect of age and cinnarizine treatment on brain dopamine receptors.
TL;DR: Chronic treatment with cinnarizine alters both D1 and D2 receptor densities, with a higher sensitivity of the D1 subtype, which could indicate that the interactions between dopamine receptor subtypes may be necessary for the full expression of behavioral events mediated by the D2 receptors.
Journal ArticleDOI
THU0275 Pharmacodynamic Modeling of BTK Occupancy versus Efficacy in RA and SLE Models Using The Novel Specific BTK Inhibitor M2951
Philipp Haselmayer,Montserrat Camps,L. Liu-Bujalski,F. Morandi,J. Head,S. Zimmerli,L. Bruns,Andrew Bender,Patricia Schroeder,R. Grenningloh +9 more
TL;DR: In mouse models of RA and SLE, M2951 displayed robust efficacy as demonstrated by a marked reduction of disease severity, and may inform rational dose decisions as M29 51 is advanced for development in rheumatologic diseases.
Patent
Pharmaceutically active sulfonamide derivatives bearing both lipophilic and ionisable moieties as inhibitors of Protein Jun-kinases
Halazy Serge,Dennis Church,Montserrat Camps,Gotteland Jean-Pierre,Rueckle Thomas,Biamonte Marco,Arkinstall Stephen +6 more
TL;DR: In this paper, the authors have proposed sulfonamide derivatives having a lipophilic moiety and which are substantially soluble under physiological conditions for use as pharmaceutically active compounds.